O'Shaughnessy Asset Management’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q3 | – | Sell |
-34,967
| Closed | -$304K | – | 1014 |
|
|
2018
Q2 | $304K | Buy |
34,967
+3,395
| +11% | +$30.5K | 0.01% | 440 |
|
|
2018
Q1 | $320K | Buy |
31,572
+18,213
| +136% | +$153K | 0.01% | 420 |
|
|
2017
Q4 | $65K | Buy |
+13,359
| New | +$65K | ﹤0.01% | 709 |
|
|
2016
Q3 | – | Sell |
-98
| Closed | -$1K | – | 1004 |
|
|
2016
Q2 | $1K | Sell |
98
-2,249
| -96% | -$15.8K | ﹤0.01% | 886 |
|
|
2016
Q1 | $16K | Buy |
2,347
+594
| +34% | +$4.37K | ﹤0.01% | 705 |
|
|
2015
Q4 | $18K | Sell |
1,753
-546
| -24% | -$6.33K | ﹤0.01% | 679 |
|
|
2015
Q3 | $27K | Buy |
2,299
+397
| +21% | +$4.39K | ﹤0.01% | 624 |
|
|
2015
Q2 | $17K | Buy |
1,902
+1,230
| +183% | +$9.29K | ﹤0.01% | 694 |
|
|
2015
Q1 | $4K | Buy |
672
+115
| +21% | +$711 | ﹤0.01% | 864 |
|
|
2014
Q4 | $3K | Buy |
557
+121
| +28% | +$704 | ﹤0.01% | 934 |
|
|
2014
Q3 | $3K | Sell |
436
-197
| -31% | -$1.2K | ﹤0.01% | 885 |
|
|
2014
Q2 | $4K | Sell |
633
-231
| -27% | -$1.55K | ﹤0.01% | 874 |
|
|
2014
Q1 | $6K | Sell |
864
-245
| -22% | -$1.69K | ﹤0.01% | 826 |
|
|
2013
Q4 | $7K | Buy |
+1,109
| New | +$7.55K | ﹤0.01% | 805 |
|
O'Shaughnessy Asset Management's JNP Position: Q3 2018 in Review
O'Shaughnessy Asset Management sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q3 2018, closing a stake of 34,967 shares — an estimated $304K sold.
O'Shaughnessy Asset Management first reported a position in JNP in Q4 2013 and held it in 14 quarters. The position peaked at $320K in Q1 2018. 0 funds tracked by Wall St. Rank hold JNP as of Q3 2018.
- O'Shaughnessy Asset Management reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
- O'Shaughnessy Asset Management sold 34,967 Juniper Pharmaceuticals, Inc. Common Stock shares in Q3 2018, an estimated $304K.
- O'Shaughnessy Asset Management first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q4 2013 and held it in 14 quarters.
- O'Shaughnessy Asset Management's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $320K in Q1 2018.
- 0 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q3 2018.
Based on O'Shaughnessy Asset Management's 13F filing for Q3 2018, filed 6 Nov 2018.